PopVax is an Indian full-stack biotech building first-in-class and best-in-class vaccines and cancer immunotherapies using machine learning-driven protein design and relentless empiricism. We design, develop, and manufacture our own RNA medicines end-to-end because we believe great pharmaceutical science can only flourish in tight feedback loops that iterate rapidly. PopVax’s experimental work and clinical dose production is based at the RNA Foundry, our integrated R&D; and GMP-capable clinical dose production facility in Hyderabad.
PopVax's north star is our goal of developing novel vaccines and therapeutics over the next decade with the cumulative ability to save 1 million lives each year – the Million Lives Mission. To that end, we are developing first-in-class vaccines against Hepatitis C, Strep A, and adult pulmonary TB; broadly-protective best-in-class vaccines against COVID-19, influenza, malaria, and HPV; and precision immunotherapies against hard-to-treat solid tumours such as liver cancer and pancreatic cancer. Beyond existing diseases,
we are leveraging our high-speed platform to build rapid-response biosecurity capabilities against engineered de novo pathogens.
Our mission is funded by Vitalik Buterin’s Balvi Fund, the Gates Foundation, the US Biomedical Advanced Research and Development Authority (BARDA), Renaissance Philanthropy, and Good Ventures, with individual investments from Enveda founder Viswa Colluru and Tesla self-driving AI pioneer Dhaval Shroff. Our first program, an open-source broadly-protective COVID-19 vaccine, will begin a Phase I clinical trial in Australia in mid-2026. This is just the start – we intend to advance 6+ novel vaccine and immunotherapy programs into human clinical trials over the next three years, decisively demonstrating that world-class biotech R&D; is possible in India.
No matter the job title, each person’s role at PopVax is ultimately about helping bring safe, effective current medicines that represent a step-change over